Glutamate racemase (MurI) has been proposed as a target for anti-tuberculosis drug development based on the inability of DmurI mutants of Mycobacterium smegmatis to grow in the absence of D-glutamate. In this communication, we identify DmurI suppressor mutants that are detected during prolonged incubation. Whole genome sequencing of these DmurI suppressor mutants identified the presence of a SNP, located in the promoter region of MSMEG_5795. RTqPCR and transcriptional fusion analyses revealed that the DmurI suppressor mutant overexpressed MSMEG_5795 14-fold compared to the isogenic wildtype. MSMEG_5795, which is annotated as 4-amino-4-deoxychorismate lyase (ADCL) but which also has homology to D-amino acid transaminase (D-AAT), was expressed, purified and found to have D-AAT activity and to be capable of producing D-glutamate from D-alanine. Consistent with its D-amino acid transaminase function, overexpressed MSMEG_5795 is able to complement both DmurI deletion mutants and alanine racemase (Dalr) deletion mutants, thus confirming a multifunctional role for this enzyme in M. smegmatis.
Introduction
Mycobacterium tuberculosis, the etiologic agent of tuberculosis (TB), latently infects one third of the world's population, and in 2015 claimed 1.8 million lives according to WHO estimates (WHO, 2015) . TB requires prolonged treatment, and nonadherence often results in the appearance of drug-resistance. Resistance to multiple drugs in TB is an ongoing threat to global health (WHO, 2017) . Of the 10.4 million TB cases reported by the World Health Organization in 2015, 480 000 people were infected with either multi-drug resistant (MDR-TB) or extremely drug resistant (XDR-TB) strains (WHO, 2017) . The treatments for drug resistant TB are often inefficacious as well as toxic, and the mortality rates of MDR-TB and XDR-TB have been reported as 63% and 88% respectively (Gandhi et al., 2012; Dheda et al., 2014; WHO, 2017) . Therefore, finding new drugs to target M. tuberculosis will be necessary to control this globally important infectious disease.
Glutamate racemase (MurI) has been proposed recently as a potential new target for inhibition by antituberculosis therapies (Li et al., 2014; Morayya et al., 2015; Poen et al., 2016; Prosser et al., 2016) . MurI is an essential enzyme in most bacteria and it is needed to provide D-glutamate for completion of the peptidoglycan layer of the bacterial cell wall (Doublet et al., 1993; Geng et al., 2008) . The murI gene has been reported as essential in E. coli (Doublet et al., 1993) , Bacillus anthracis (Oh et al., 2015) , B. subtilis (Kimura et al., 2004) , Helicobacter pylori (Lundqvist et al., 2007) and Streptococcus pneumoniae (de Dios et al., 2002) , among others. Recent work has confirmed its essentiality in both M. smegmatis (Li et al., 2014) and M. tuberculosis (Morayya et al., 2015; Griffin et al., 2011) , contradicting earlier studies (Sassetti et al., 2003; Harth et al., 2005) .
Glutamate racemase is known as a druggable enzyme and it has been targeted successfully in inhibitor development programs directed at S. pneumoniae, H. pylori and Enterococcus faecalis (de Dios et al., 2002; Fisher, 2008; Geng et al., 2008; Geng et al., 2009) . Recently the crystal structures of MurI from both M. smegmatis and M. tuberculosis have been solved and analyzed in comparison to other available MurI structures (Poen et al., 2016) , and found to be promising templates for inhibitor development. Another recent report has found the alanine racemase inhibitor, b-chloro-D-alanine, binds to and effectively targets mycobacterial MurI (Prosser et al., 2016) . Given MurI's essential nature in mycobacteria, and given its track record of yielding potent inhibitors in drug development programs, it could be a promising potential source of new anti-tuberculosis agents.
In many bacteria, MurI is the only source of D-glutamate, but in some bacteria another enzyme, D-amino acid transaminase (D-AAT), can synthesize D-glutamate (Fotheringham et al., 1998) . Different combinations of these two enzymes have been reported in various bacterial species. For example, in B. anthracis (Oh et al., 2015) and B. subtilis (Kunst et al., 1997; Kimura et al., 2004) , two isoforms of MurI and a single isoform of D-AAT enzyme are present. In Listeria monocytogenes (Thompson et al., 1998; Majorek et al., 2009) , Staphylococcus aureus and S. haemolyticus (Pucci et al., 1995) all three have a MurI and a D-AAT in their genomes. Consistent with recent findings of MurI essentiality, a D-AAT enzyme has not been identified experimentally or in genomic annotations, in M. smegmatis. However, recent proteomic studies have pointed to the possibility of a D-AAT in the mycobacterial genome that could be involved in D-amino acid metabolism, but to date it has not been identified (Halouska et al., 2014; Marshall et al., 2017) .
All recent studies support the conditional essentiality of MurI in mycobacteria (Li et al., 2014; Morayya et al., 2015) , but it is unknown if its deletion results in a bactericidal or bacteriostatic effect. Further, it is unknown how readily resistance can develop to this deletion (Leekha et al., 2011) . To explore the nature of the effect of murI deletion on bacterial growth we set up prolonged incubation of D-glutamate auxotrophic DmurI strains in the absence of D-amino acids in an attempt to select for strains with a revertant phenotype (Pankey and Sabath, 2004) . Here we report evidence that murI deletion in M. smegmatis is initially bacteriostatic, and we describe the consistent development of suppressor mutants during prolonged incubation. Further we find that this mutation results in the overexpression of MSMEG_5795, a gene most often annotated as 4-amino-4-deoxychorismate lyase (ADCL) gene, but which we show has D-amino acid transaminase activity.
Results
Isolation and characterization of murI suppressor mutants of M. smegmatis
Previous work from our group demonstrated that glutamate racemase deletion mutants of M. smegmatis mc 2 155 were unable to grow in the absence of D-glutamate (Li et al., 2014) . To investigate this further, we set up growth experiments in which the incubation period was extended to > 100 h, both in the absence and presence of D-glutamate (Fig. 1) . In the presence of D-glutamate, wild-type and DmurI strains grew to a maximum OD 600 of approximately 3.5 by about 70 h (Fig. 1A) . In the absence of Dglutamate, the wild-type and genetically complemented DmurI strains grew as before. The DmurI mutant initially Fig. 1 . Growth curves and cell viability curves for M. smegmatis DmurI strains. Growth curves for M. smegmatis mc 2 155-Otago (wild-type) (black curve), DmurI (brown curve) and murI complemented DmurI (green curve) strains. For (A) and (B) the x-axis represents hours of incubation and the y-axis represents the OD 600 of the cultures. For (C) CFU ml 21 is plotted on the y-axis. The arrows indicates the point at which the inoculum was washed and new medium was introduced. Error bars represent one standard deviation. A. Growth curves in D-glutamate supplemented minimal medium. B. Growth curves in minimal medium without D-glutamate supplementation. C. Colony counts from the cultures shown in (B).
D-amino acid transaminase (D-AAT) from Mycobacterium smegmatis 199
failed to grow in the absence of D-glutamate, but prolonged incubation (> 100 h) resulted in eventual growth (Fig. 1B) . Cell viability of the DmurI mutant, which was grown without D-glutamate supplementation, was determined and revealed an initial 1-2 log drop in cell count followed by growth recovery beginning at about 80 h, which by 150 h was close to wild-type levels (Fig. 1C) . Growth curves were repeated (six replicates) with wild-type, murI deletion mutants, complemented mutants and putative suppressor mutants ( Fig. 2A) . Comparable growth kinetics as observed in Fig. 1 were obtained each time. Importantly, the DmurI strain exhibited the same period of nongrowth, whereas the suppressor mutants grew like wild-type cultures and did not require re-adaptation to grow in the absence of Dglutamate even following multiple passages of growth in Dglutamate supplemented media ( Fig. 2B and C) .
DmurI suppressor mutants reveal a consistent genetic change between MSMEG_5795 and 5796
The complete genome sequences of wild-type M. smegmatis, DmurI and three putative DmurI suppressor mutants, which we termed S-1, S-2 and S-3, were determined as described in Methods. Initial read mapping to the reference M. smegmatis mc 2 155 (NC_008596) genome identified 130 variations (SNPs and indels). Taking into account these 130 variations, a custom reference genome for our M. smegmatis mc 2 155 strain was then created for the analysis of the suppressor mutant genotypes (Mohan et al., 2015) .
DNA Sequence coverage of the M. smegmatis genomes averaged 136-fold and is illustrated for the wild-type strain mc 2 155 (Supporting Information Fig.   S1 ). The presence of the complete murI gene in the wild-type strain and the 540 bp deletion of the murI gene in both the DmurI and suppressor mutants is evident in the read coverage. To identify the genetic change responsible for the suppressor mutant phenotype, the sequencing data was analyzed to identify the SNPs with the highest variant frequency. SNPs that were present in the three putative DmurI suppressor mutants, but absent in the wild-type or the DmurI mutant are profiled in Table 1 and Supporting Information Table  S2 . Of these, one SNP mutation, SNP_3, was present in all three putative DmurI suppressor mutants and is found between MSMEG_5795 and MSMEG_5796. Two other SNP mutations were found in two of the putative suppressor mutants and involved either MSMEG_4918 or MSMEG_0516. SNP_3 is present in the 100 bp intergenic region between MSMEG_5795 and MSMEG_5796. It is not present in the wild-type or DmurI mutant, and consists of a cytosine to thymine (C!T) mutation on the 3 0 !5 DNA strand 30 nucleotides (nt) upstream of MSMEG_5795. From the perspective of the 5 0 !3 0 DNA strand, this SNP would be a guanine to adenine (G!A), change located at 71 nt upstream of MSMEG_5796 (Table 1 ). In the 100 bp intergenic region, two putative promoter sites were identified. A 5 0 -TAGAGT-3 0 consensus promoter sequence was identified 6 nt upstream of MSMEG_5796 gene on the 5 0 !3 0 strand in both M. smegmatis and M. tuberculosis (Fig. 3) . This sequence matches with the 210 promoter sequence found for Rv3418c (10 kDa/groES) of M. tuberculosis, S6 of M. smegmatis, and ML0381 (groEL1) of M. leprae (Kalate et al., 2003) , but is not affected by the SNP identified here. Conversely, the SNP_3 change we identified is within a second promoter sequence, 5 0 -TACGCT-3 0 , which is located on the 3 0 !5 0 DNA strand 26 nt upstream of MSMEG_5795. The SNP results in the sequence becoming 5 0 -TATGCT-3 0 (Fig. 3) . The 5 0 -TACGCT-3 0 promoter sequence is present elsewhere in mycobacteria, for example, at the 210 position of Rv1819c (ABC transporter) in M. tuberculosis (Vallecillo and Espitia, 2009 ) and at the 210 position of the bla gene in M. fortuitum (Timm et al., 1994b) . This promoter sequence is recognized by SigA (Vallecillo and Espitia, 2009) .
MSMEG_5795 codes for a protein annotated as 4-amino-4-deoxychorismate lyase (ADCL). This annotation is found in the NCBI, the TBDB (Reddy et al., 2009; Galagan et al., 2010) , and MicrobesOnline databases (Dehal et al., 2010) , as well as the webTB and SmegmaList databases (Kapopoulou et al., 2011) . However, in a minority of cases, it has been annotated additionally as an amino acid transaminase (Dehal et al., 2010) . The homologue of MSMEG_5795 in M. tuberculosis is Rv0812, and is annotated both as a deoxychorismate lyase and an amino acid aminotransferase in the TBDB and TubercuList databases (Kapopoulou et al., 2011) . ADCL catalyzes the PLP dependent conversion of 4-amino-4-deoxychorismate (ADC) to p-aminobenzoate and pyruvate (Nakai et al., 2000) . This enzyme has been found to be essential in E. coli (Green et al., 1992) , Pseudomonas aeruginosa (Hoang et al., 1998) , (Soda and Esaki, 1985) . Therefore, if MSMEG_5795 is able to function as a D-AAT then SNP_3 could significantly impact D-glutamate synthesis. MSMEG_5796 encodes a protein that is a part of the glycine cleavage multi-enzyme complex (MEC). The complex is present in bacteria and the mitochondria of eukaryotes (Motokawa and Kikuchi, 1971) and catalyzes the formation of N 5 , N 10 -methylenetetrahydrofolate, which is utilized for the biosynthesis of purines, thymidylate and methionine (Kikuchi et al., 2008) . Therefore, this enzyme is unlikely to participate in D-glutamate biosynthesis.
Suppressor mutant strains S-2 and S-3 contain two SNPs in common, but which are unlikely to affect D-glutamate metabolism. For example, they contain a SNP located 859 nt downstream from the translational start site of MSMEG_4918, which codes for a 1,4-alpha-glucan branching enzyme. This SNP is not present in S-1, wild-type or the DmurI mutant (Table 1) . S-2 and S-3 contain another SNP located 188 nt downstream from start site of MSMEG_0516, which codes for a protein involved in sugar transport. This change involves a thymine to guanine (TfiG) change and is not present in strains S-1, wild-type or DmurI mutant strains (Table 1) . As these two genes are unrelated to D-amino acid synthesis or metabolism they would not be likely to affect Dglutamate levels. Notably, a homologue of MSMEG_0516 is not present in M. tuberculosis.
SNP_3 significantly increases MSMEG_5795 expression
The effect of SNP_3 on the expression of MSMEG_5795 and MSMEG_5796 was quantified using RT-qPCR. The expression of MSMEG_5795 was found to be 14-fold higher than wild-type for suppressor mutants 2 and 3, and threefold higher for suppressor mutant 1 (Fig. 4A) . The changes for suppressor mutants 2 and 3 were statistically significant (P < 0.05). The expression of MSMEG_5796 was 0.89 to 2.78-fold higher in the DmurI suppressor mutants than in the wild-type strain, but this change was not statistically significant (Fig. 4B ). The expression of both these genes in the DmurI mutant was also studied and was not significantly different from wildtype (Fig. 4) . RT-qPCR data for wild-type, DmurI, and putative suppressor DmurI strains S-1, S-2 and S-3. The target/reference ratio is plotted on the y-axis where '*' indicates statistical significance at P < 0.05. Error bars represent one standard deviation. To explore whether the increased expression of MSMEG_5795 in our suppressor mutants was due to increased promoter activity, we monitored the activity of the altered MSMEG_5795 promoter using promoter-lacZ fusion constructs created in pJEM15 in M. smegmatis mc 2 155. All transformed bacteria grew well reaching a maximum OD 600 5 3.0 after about 36 h. Compared to an empty vector included as a control, the pJEM15 vector containing the wild-type promoter for MSMEG_5795 had measurable promoter activity which gradually increased from about 50 Miller units (MU) in the early exponential phase to about 100 MU in the stationary phase ( Fig. 5 ). Wild-type strains transformed with a construct containing the promoter from DmurI suppressor mutants displayed 150 MU in the early exponential phase followed by an increase to ca. 200 MU in the stationary phase (Fig. 5C ), which is roughly twofold higher promoter activity than wild-type. These data suggest that the SNP_3 mutation we identified in the promoter leads to significant overexpression of the MSMEG_5795 gene, and is consistent with the RT-qPCR results reported above in which MSMEG_5795 was found to be 14-fold higher in the DmurI suppressor mutants compared to wild-type.
The expression of MSMEG_5795 is insensitive to D-alanine and D-glutamate
The activity of the MSMEG_5795 promoter-lacZ fusion constructs was examined for modulation by the cell wall components D-alanine and D-glutamate. The wild-type control MSMEG_5795-lacZ fusion construct reached a maximum OD 600 5 3.0 at 36 h and was found to have 50-100 MU from exponential phase to stationary phase (Fig. 6A ). The addition of either 10 mM D-alanine or 10 mM D-glutamate did not significantly alter the MU measurements with 80-100 MU measured over the exponential to stationary phases for the former (Fig. 6B ) and 50-90 MU for the latter (Fig. 6C) . Interestingly, following the addition of D-alanine, the maximum OD 600 reached 3.5 after 40 h which was slightly higher than the control or the D-glutamate growth curves (Fig. 6) . Strains containing the mutated promoter were examined as above. The MSMEG_5795_SNP_3-lacZ fusion construct reached a maximum OD 600 5 3.0 at around 36 h and its promoter activity was measured from exponential phase to stationary phase at 150-200 MU (Fig. 6D ). When this strain was grown following the addition of D-alanine, the promoter activity was measured at 140-180 MU over the exponential to stationary phase of the growth (Fig. 6E) . For the cultures containing D-glutamate a trend toward higher promoter activity of 180-220 MU was noted over the exponential to stationary phase of the growth (Fig. 6F) . A slightly higher OD 600 maximum of around 3.5 was again reached for the D-alanine containing culture.
Therefore, wild-type MSMEG_5795 expression does not appear to be modulated by D-alanine and D-glutamate. This is consistent with its promoter being potentially recognized by SigA factor, which regulates constitutive or housekeeping genes in Mycobacterium sp. (Manganelli et al., 2004) .
Increased expression of MSMEG_5795 complements both DmurI and Dalr mutants
The ability of MSMEG_5795 to complement the DmurI mutant was investigated further by providing MSMEG_5795 in trans under control of the suppressor mutant promoter as well as the wild-type promoter. It was found that providing the gene along with the suppressor mutant promoter was sufficient to complement the DmurI mutant directly, with cultures growing to a maximum OD 600 3.5. This growth is similar to the wild-type strain and to DmurI strains complemented with D-glutamate (Fig. 7A ). This result suggests that the MSMEG_5795 gene product is capable of synthesizing D-glutamate directly or stimulating its production.
Providing MSMEG_5795 under control of the wildtype promoter did not initially complement the DmurI strains, but following 55 hours of incubation growth recovery did occur. This period is 25 h faster than the 80 h seen with DmurI mutants (Fig. 7A) . The failure to initially complement suggests that the amount of Dglutamate synthesis from the wild-type promoter is insufficient to cause the DmurI revertant phenotype, and that the overexpressing mutation is needed. Also, presumably having a second copy of the MSMEG_5795 gene in the chromosome would increase the chance of an overexpressing mutation involving either of the promoters.
To further analyze the function of the MSMEG_5795 gene product, we introduced it into the Dalr mutant (DM22) that we have previously reported (Milligan et al., 2007) . This strain is auxotrophic for D-alanine and, as expected, the wild-type strain and the D-alanine supplemented Dalr mutant both grow normally and reach their maximum OD 600 of 3.0-3.5 after 30-36 h. When the Dalr mutant, incubated without D-alanine, was complemented with MSMEG_5795 gene under its native promoter it did not grow. However, when MSMEG_5795 gene was provided in trans under control of the suppressor mutant promoter, the Dalr mutant was able to grow, albeit, with an altered growth phenotype requiring 55 h to reach a maximum OD 600 of about 2.5 (Fig. 7B) .
The MSMEG_5795 protein has significant D-amino acid transaminase activity
To investigate the D-amino acid transaminase activity of the protein product of MSMEG_5795, it was expressed and purified from M. smegmatis mc 2 4517 using immobilized metal affinity and size exclusion chromatography. Using this method, milligram quantities of homogenous protein were produced (Fig. 8A ). This protein was assayed for D-AAT activity following a protocol from (Tanizawa et al., 1987 (Tanizawa et al., , 1989 . Its V max was identified as 13.8 U mg 21 and its K M for D-alanine was 10.2 mM (Fig. 8B ). In addition, the apparent K M for pyridoxal phosphate (PLP), which D-AAT is known to use as a co-factor, was found to be 75.4 mM. The purity of the MSMEG_5795 preparation was confirmed by SDS-PAGE (Fig. 8A) and by liquid chromatography coupled nanospray LTQ-Orbitrap tandem mass spectrometry (LC-MS/MS) of tryptically digested proteins excised from an SDS-PAGE gel band. Using this method, the MSMEG_5795 protein was identified with more than 83% sequence coverage from a heavily loaded central band, as well as in flanking minor bands (see Fig. 8A , lane G for a representative Coomassie stained gel). The upper minor band is predominantly a dimer of MSMEG_5795, but also contains the 60 kDa chaperonin of M. smegmatis as a minor contaminant. Very minor signal intensities were detected for other negligible contaminants and none of these additional proteins would suggest a contaminating transaminase activity. As a further check for contaminating proteins that might not stain with Coomassie, we analyzed an insolution sample of our purified protein using mass spectrometry, as outlined in the updated Supporting Information material, and again did not identify any protein with contaminating transaminase activity.
To confirm the ability of MSMEG_5795 to produce significant quantities of glutamate from D-alanine, the production of glutamate was confirmed by high resolution mass spectrometry (Fig. 8C) . The m/z signal of singly protonated glutamate at 148.06044 was clearly detected with a mass accuracy of less than 0.0001 mass units (Supporting Information Figs. S2 and S3) . The concentration of glutamate increases with incubation time from 0.3 mM at 20 min to 0.7 mM at 40 min and finally to 1.0 mM at 60 min respectively. Additional proof of glutamate production by MSMEG_5795 was obtained by inputting the product of the D-AAT assay as the "substrate" for the coupled glutamate racemase assay which showed time dependent glutamate production (Poen et al., 2016) (Supporting Information Fig. S4) .
Lastly, we have also shown that DmurI deletion mutants can be grown in media supplemented with 10 mM D-alanine, for which we observe growth rates and maximum OD 600 values consistent with wild-type strains (Fig. 9 ). This result is consistent with the MSMEG_5795 protein acting via its D-AAT activity, at a substrate value close to its K M , to produce D-glutamate from D-alanine. 
Discussion
The M. smegmatis DmurI deletion was initially bacteriostatic for growth in the absence of D-glutamate, but prolonged incubation resulted in the generation of suppressor mutants that mapped to the promoter of MSMEG_5795, an uncharacterized gene which is annotated predominately as a 4-amino-4-deoxychorismate lyase (ADCL). Promoter mutations in the suppressor mutants activated the expression of MSMEG_5795 14-fold relative to the wild-type, and these same promoter mutants provided in trans were able to complement DmurI, as well as Dalr, mutants.
Biochemical characterization of MSMEG_5795 shows that it has significant D-amino acid transaminase (D-AAT) activity. For example, we have carried out the D-AAT assay using D-alanine and ketoglutarate and determined a clear and significant V max and K M for this activity. Next, we have taken the output of this assay and shown that it is glutamate using mass spectrometry. We have also shown that this output can serve as input into the glutamate racemase assay. Finally, we show the output of MSMEG_5795, when it is overexpressed, it is able to complement DmurI deletion mutants.
Recently, investigators have predicted the presence of a metabolically important D-AAT enzyme in mycobacteria. This conclusion was based on metabolomic studies that pointed to a shunt from D-glutamate to D-alanine (Marshall et al., 2017) . Potential candidates for genes with D-AAT activity in mycobacteria were explored in these articles, but MSMEG_5795 was not implicated (Halouska et al., 2014) . The results of the current study unequivocally establish significant D-AAT activity for the gene product of MSMEG_5795, which we have now shown is capable, in the context of an overexpression mutant, of complementing murI deletion and suggest that MSMEG_5795 is the much-sought after mycobacterial D-AAT.
Our findings may have implications for the use of glutamate racemase inhibitors as anti-tuberculosis drugs. Characterization of the gene product of MSMEG_5795. A. SDS-PAGE analysis of the overall purification of the MSMEG_5795 protein. M, Molecular weight marker with sizes indicated in kDa; W, Whole cell lysate; S, Soluble protein; I, Sample pooled after immobilized metal affinity chromatography; G, Sample pooled after size exclusion chromatography. B. Steady state kinetic parameters for the MSMEG_5795 protein using a coupled enzyme assay for D-amino acid transaminase were determined at substrate concentrations from 0.20 to 25.0 mM Dalanine. The average value of the duplicate measurements is shown for each substrate concentration with standard deviation shown as an error bar. Activity at substrate concentrations of 0.78 and 6.25 mM D-alanine were measured in triplicate. The velocity (in nM min 21 ) was plotted against the substrate concentration (in mM), and used to determine the kinetic parameters for MSMEG_5795 with corresponding standard error. Each assay was performed at a final concentration of MSMEG_5795 of 77 nM. C. Detection of glutamate production by mass spectrometry. Duplicates of the enzyme assays for D-amino acid transaminase were incubated for 20, 40 and 60 min and the amount of glutamate produced was measured as the ratio of peak intensities of singly protonated glutamate at m/z 148.060 versus the constant concentration of singly protonated aspartate at m/z 134.045 by direct infusion mass spectrometry. The concentration of glutamate was calculated based on a glutamate standard curve as described in Methods.
The homologue of MSMEG_5795 in M. tuberculosis is Rv0812. If Rv0812 codes for a protein with significant D-AAT activity this could mean that glutamate racemase inhibitors would be prone to develop resistance rapidly, via overexpression mutants of Rv0812. However, it is important to be cautious in comparing these two organisms given that their natural habitat, growth characteristics and genetic background are so very different. Also, some bacteria are unable to use their D-AAT genes to rescue D-glutamate auxotrophs. For example, yheM, which is the D-AAT gene in B. subtilis, does not rescue its D-glutamate auxotroph (Kimura et al., 2004) . Also, given that, to avoid the development of resistance, antituberculosis drugs are never given alone, it may be that this will not be an important concern for glutamate racemase inhibitors.
Therapies that target enzymes involved in interdependent aspects of cell wall precursor synthesis, such as glutamate racemase and alanine racemase, or D-AAT and glutamate racemase, might be able to exploit the interrelationships between these enzymes. For example, the revertant is able to synthesize D-glutamate from Dalanine with D-alanine coming from alanine racemase acting on L-alanine, which is plentiful. However, it is likely that double mutants involving both racemases such as DmurI-Dalr would not be capable of reversion because neither D-alanine nor D-glutamate would be available as cell wall precursors, and even a metabolically hyperactive D-AAT would be unable to complement for simultaneously missing both cell wall components. Similarly, double deletion mutants such as, DmurI-DMSMEG_5795 would not be able to synthesize D-glutamate for cell wall biosynthesis, even if D-alanine is available. Therefore, drugs targeting a combination of MurI and Alr or MurI and MSMEG_5795 enzymes or all three enzymes could have synergy against tuberculosis. Intriguingly it has been reported by other investigators that, when used against mycobacteria, there is synergy between D-cycloserine and b-chloro-D-alanine (David, 2001; Prosser et al., 2016) . Perhaps some of this synergy could be due to its action on both of these two racemases, although to be sure the situation is complex given that D-cycloserine itself is targeting at least two enzymes (Lambert and Neuhaus, 1972; Chacon et al., 2002; Feng and Barletta, 2003; Prosser and de Carvalho, 2013) .
Finally, while we have shown that MSMEG_5795 functions as a D-AAT enzyme, we have not ruled out that it may also be able to function as ADCL. These two enzymes are closely related. Both enzymes utilize PLP as a co-factor. The active site structure of ADCL is homologous to some transaminases, including D-amino acid transaminases (D-AAT) (Nakai et al., 2000) . The ADCL protein in E. coli and MSMEG_5795 share 29% identity, higher than the 23% identity shared by the Damino acid transaminase of B. subtilis and MSMEG_5795, which likely explains the predominant annotation of MSMEG_5795 as an ADCL. Notably, the D-AAT activity we measured for the MSMEG_5795 protein is significant at V max of 13.8 U mg 21 but is less than the V max of 200 U mg 21 reported for the Bacillus enzyme (Van Ophem et al., 1995) . This could explain why wild-type MSMEG_5795 under control of its native promoter is unable to rescue DmurI or Dalr deletion strains. Successful complementation requires overexpressing MSMEG_5795 mutants in M. smegmatis. This implies that the concentration of substrate or the activity of the enzyme in the wild-type strain is too low to provide sufficient D-glutamate or D-alanine production in DmurI or Dalr mutants respectively. Therefore, it could be that MSMEG_5795 does, in fact, code for ADCL, and that its D-AAT activity is a "moonlighting" function, which 
Conclusions
In M. smegmatis, we have established that the murI gene deletion has a bacteriostatic phenotype which can be rescued by overexpression mutants of MSMEG_5795. We have also shown that MSMEG_5795 is able to act as a D-amino acid transaminase, during the reversion of this phenotype. Therefore, MSMEG_5795 has significant D-AAT activity, in addition to, or instead of its annotated ADCL function. Based on this functional characterization, a revision of the annotation for MSMEG_5795 and its homologues in mycobacteria is recommended. In M. tuberculosis, the homologue to MSMEG_5795 is Rv0812. It should be studied to see if it has D-AAT activity which could have an effect on DmurI and Dalr deletion strains.
Experimental procedures
Bacterial strains, media and growth conditions
All strains and plasmids used in this study are listed in Table 2 or Supporting Information Table S1 . Plasmid propagation was carried out in E. coli strains, which were grown in Luria-Bertani (LB) medium at 378C with agitation (220 rpm) or on LB 1.5% agar plates with appropriate antibiotics. Kanamycin was added at 20 lg ml 21 for M. smegmatis, and 50 lg ml 21 for E. coli, hygromycin B at 50 lg ml 21 for M. smegmatis, and 200 lg ml 21 for E. coli. Mycobacterium smegmatis strain mc 2 155 (Snapper et al., 1990 ) and derived strains were maintained on LB agar plates supplemented with 0.05% (w/v) Tween 80 (LBT) with additions as indicated (e.g., 60 mM D-glutamate). For liquid culture, M. smegmatis strain mc 2 155 was grown at 378C with agitation [Erlenmeyer flasks (50 ml), 220 rpm] in Hartmans-de Bont (HdB) minimal medium (Hartmans and Bont, 1992) supplemented with 0.05% Tween 80 (Sigma Aldrich) and appropriate carbon sources where indicated.
Growth was monitored by optical density measurements at 600 nm (OD 600 ) using culture samples diluted in PBSTween 80 to bring OD 600 to below 0.5 when measured in cuvettes of 1 cm-light path length in an Ultrospec TM 3100 pro (GE Healthcare Life Sciences). Media were inoculated to an initial OD 600 of 0.001-0.005. Growth rates were determined by plotting the log 10 of the OD 600 versus time. For determination of cell viability (CFU ml 21 ), the Miles-Misra method was used (Miles et al., 1938) . Briefly, the experimental procedure was as follows: Cells pellets from 1 ml culture aliquots were washed with PBS-Tween 80 and resuspended in 1 ml buffer. Ten-fold serial dilutions of 10 21 to 10 26 were made and 5 ll aliquots were used to inoculate LBT plates supplemented with 60 mM D-glutamate. For each dilution, four technical replicates were carried out. After inoculation, the plates were incubated at 378C for three days.
Isolation and characterization of DmurI suppressor mutants M. smegmatis DmurI mutants were grown in HdB minimal medium containing 15 mM D-glutamate until an OD 600 of 0.3 was reached. Cells were harvested by centrifugation and washed with sterile PBS-Tween 80 buffer to remove external D-glutamate. Following re-suspension, the cells were used to inoculate fresh growth medium without D-glutamate supplementation to an OD 600 of approximately 0.001. Cultures were incubated with shaking and DmurI suppressor mutants that grew after ca. 80 h of incubation at 378C were diluted and plated onto LBT agar containing 60 mM D-glutamate. Single colonies of putative suppressor DNA manipulation and whole genome sequencing
All molecular biology techniques were carried out according to standard procedures (Sambrook et al., 1989 (Andrews, 2010) to show read length, number and quality. Adapter/vector sequences were then removed using BLAST and the UniVec databases. The paired-end reads were then imported into Geneious (Kearse et al., 2012) and run through FLASH (Magoc and Salzberg, 2011) and were then mapped to the reference M. smegmatis mc 2 155 (NC_008596) genome using the read mapper. Polymorphisms in the mapped reads (SNPs and indels) were identified with any variants at 50% frequency or above being added. Exported files were then checked and handled using Geneious and SAMtools (Li et al., 2009) , annotated and exported for analysis. The read coverage of the mycobacterial genome was visualized using the Blast Ring Image Generator developed by Scott Beatson's group (Alikhan et al., 2011) . The resulting sequencing data were submitted to the NCBI Nucleotide Archive (PRJNA362630).
RNA extraction and reverse transcriptase PCR
Total RNA was extracted using TRIZOLV R reagent. Cell lysis was achieved by three cycles of bead beating in a MiniBeadbeater (Biospec) at 5000 rpm for 30 s. DNA was removed from the RNA preparation by treatment with 2 U RNase-free DNase using the TURBO DNA-free kit (Ambion) according to the manufacturer's instructions. The quality of RNA was checked on a 1% agarose gel and the concentration was determined using a NanoDropV R ND-1000 spectrophotometer. The Reverse Transcriptase (RT) reactions were carried out using 1 lg of RNA template and gene-specific primers (Supporting Information Table S1 ). The RT reactions and the quantitative PCR were carried out using the PrimeScript RT Reagent Kit (Perfect Real Time) (TaKaRa) following manufacturer's instruction with real-time PCR being performed using a LightCyclerV R 480 System (Roche).
Construction of lacZ reporter constructs and complementation of DmurI suppressor mutants
To study MSMEG_5795 expression, transcriptional fusions of the MSMEG_5795 promoter were cloned into the shuttle vector pJEM15 (Timm et al., 1994a) , a plasmid containing a promoterless lacZ gene. A 615 bp PCR product encompassing the MSMEG_5795 (-505 to 1110) promoter region was amplified from the wild-type strain and from a suppressor mutant (KKRM146) using the primers msDAAT-lacZ_FW and msDAAT-lacZ_RV (Table 2 ). The amplified product was cloned into ScaI and BamHI sites of pJEM15. Chemically competent E. coli DH10B was transformed with these plasmids via heat shock. Plasmid constructs were extracted and fidelity confirmed using restriction digestion and DNA sequencing before electroporation into M. smegmatis mc 2 155. The transcriptional activity of the MSMEG_5795 gene was determined using the b-galactosidase assay as described previously by (Gebhard et al., 2006) . For MSMEG_5795 complementation experiments, a region of the MSMEG_5795 gene that comprised 2505 bp upstream and 1115 bp downstream was amplified (totaling 1490 bp) from both wild-type and DmurI suppressor mutant strains (KKRM146). For this amplification, the msDAAT_NativeP KI_FW and msDAAT_NativeP KI_RV primer pair was used (Supporting Information Table S1 ). The 1490 bp products were cloned into EcoRV and HindIII sites of the integrating shuttle vector pUHA267 (Supporting Information Table S1 ). The plasmid constructs were purified from E. coli DH10B and confirmed by restriction digestion and sequencing. Plasmids were electroporated into DmurI and Dalr M. smegmatis mutant strains for downstream phenotypic analysis.
Expression and purification of MSMEG_5795
The open reading frame for MSMEG_5795 (4-amino-4-deoxychorismate lyase) was synthesized with an N-terminal His-tag and a cleavable tobacco etch virus (TEV) protease recognition sequence and inserted into pYUB28b vector (Bashiri et al., 2010) by Genscript (USA). The vector containing the MSMEG_5795 sequence was transformed into M. smegmatis mc 2 4517 cells via electroporation. Cells were grown in Luria-Bertani (LB) Miller Broth containing 0.05% (w/v) Tween 80 and supplemented with 50 mg ml 21 kanamycin and 50 mg ml 21 hygromycin. Overexpression of MSMEG_5795 was induced with 0.2% (v/v) acetamide at OD 600 0.5, cells were further incubated for 6 h at 378C and harvested by centrifugation. Cell pellets were resuspended in 20 mM Tris-HCl pH 7.4, 250 mM sodium chloride, 20 mM imidazole and 0.5 mM pyridoxal 5 0 -phosphate (PLP) and lysed by sonication. Cell lysate was centrifuged and loaded onto a 5 ml His-Trap TM FF Crude column (GE Healthcare). After removing unbound protein, MSMEG_5795 was eluted by increasing the imidazole concentration to 0.5 M. Fractions with MSMEG_5795 protein were further purified with a HiLoad TM 26/60 Superdex TM 75 prep grade column (GE Healthcare). The gel filtration buffer contained 20 mM Tris-HCl, pH 8.0 and 150 mM NaCl. Purity of samples were assessed with SDS-PAGE and protein concentration was determined using the Coomassie Plus TM Protein Assay reagent (Thermo Fisher).
D-amino acid transaminase (D-AAT) from Mycobacterium smegmatis 209
Biochemical and kinetic analysis of MSMEG_5795 MSMEG_5795 activity was assayed using the coupled enzyme D-amino acid transaminase (D-AAT) assay described by Tanizawa and colleagues (1987) in which Dalanine and a-ketoglutarate are converted to D-glutamate and pyruvate by D-AAT. Pyruvate is then converted to L-lactate by lactate dehydrogenase coupled to NADH oxidation at 308C. The decrease in absorbance at 340 nm was then measured on an Ultrospec TM 3100 pro with SWIFT II software and analyzed using GraphPad Prism version 7.00 for Windows (GraphPad Software, La Jolla, C, USA). Each reaction mixture contained 100 mM Tris-HCl pH 8.1, 10 mM a-ketoglutarate, 0.15 mM PLP, 5 U L-lactate dehydrogenase and 0.2 mM NADH. The enzyme concentration used for the assays was 77 nM. Each reaction mix was preincubated at 308C for 5 min and the absorbance at 340 nm was measured for 2 min to set a baseline. The reaction was started by adding various concentration of D-alanine (25.0, 12.5, 6.25, 3.13, 1.57, 0.78 0.39 and 0.20 mM) to the assay mix and rates were measured for 30 min at 308C. To determine the apparent K M of D-AAT for PLP, the enzyme and D-alanine concentration were fixed to 77 nM and 25 mM respectively. Assays were performed as described above in the presence of different concentrations (400, 200, 100, 50, 1 and 0 mM) of the PLP cofactor.
Mass spectrometry detection of glutamate produced by MSMEG_5795
The formation of glutamate by MSMEG_5795 was directly determined by high resolution orbitrap mass spectrometry by assaying only the first reaction of the coupled D-AAT assay following protein removal (see description next paragraph). The first reaction of coupled D-AAT assay was performed with concentrations of MSMEG_5795 of 77 nM and D-alanine of 25 mM. All other components required for the first reaction were added as described above. The reaction mixtures were incubated for 20, 40 and 60 min. The negative control contained water instead of D-alanine and was incubated for 60 min. All reactions were performed in duplicate. Following incubation, the reaction mixtures were filtered through an ultrafiltration membrane with a molecular weight cut-off of 10 kDa to remove the MSMEG_5795 protein. One ml of each filtrate (containing the low molecular weight compounds) was diluted with 98 ml of 5% acetonitrile and 0.2% formic acid in water (solvent A) and supplemented with 1 ml of 10 mM aspartate as a reference compound. Five ml of each sample were then injected by direct infusion into a nanospray coupled LTQ-Orbitrap XL mass spectrometer (Thermo Scientific, San Jose, CA) at a flow rate of 800 nl of solvent A per min. All mass measurements were performed in the orbitrap mass analyser at a resolution of 100 000 at m/z 400. Every full MS scan in the mass range of m/z 125-180 was followed by two pseudo selected reaction monitoring (pSRM) measurements of m/z 134.045 (singly protonated aspartate) and 148.060 (singly protonated glutamate). The isolation window for precursor selection was set to 3 Da and the normalized collision energy was kept at 0 to allow for an intact precursor ion measurement in the orbitrap. The relative amount of glutamate was measured as the ratio of the glutamate peak intensity versus the peak intensity of the constant amount of spiked aspartate to compensate for fluctuations in ionization and sample interferences. For the determination of the concentration of glutamate in the reaction mix an external standard curve of increasing glutamate concentration at a constant aspartate concentration was prepared as described in Supporting Information Fig. S2 .
Glutamate racemase assay detection of glutamate from MSMEG_5795
To detect the D-glutamate production by MSMEG_5795, the first step of D-AAT assay was performed as described above for the characterization of MSMEG_5795. Each assay contained 77 nM MSMEG_5795 and 25 mM D-alanine. For this experiment, the absorbance was monitored at 340 nm for 20, 40 and 60 min; each assay was performed in duplicate. The negative control contained water instead of D-alanine and was assayed for 60 min. Each reaction was stopped by transferring the reactions to 48C. MSMEG_5795 and L-LDH, were removed immediately using an ultrafiltration membrane (Vivaspin2 with 10 kDa MWCO, GE Healthcare), and the protein free filtrate was utilized for subsequent analysis by mass spectrometry.
The protein-free output of the D-AAT assay was also used as substrate for the glutamate racemase (MurI) activity to show that it contained significant quantities of glutamate. The MurI assay was performed as previously described by Poen and colleagues (2016) . Each 1 ml assay mix contained 50 mM CHES (N-Cyclohexyl-2-aminoethanesulfonic acid) pH 9.2, 5 mM nicotinamide adenine dinucleotide, 37.5 U ml 21 L-glutamate dehydrogenase, 2.5 mM adenosine 5 0 -diphosphate, 0.65 mM iodonitrotetrazolium chloride, 2 U ml 21 diaphorase. The reaction was initiated by the addition of glutamate racemase from B. anthracis to a final concentration of 10 mM, and contained 100 ml of the D-AAT assay output as substrate. The absorbance was monitored at 500 nm on an Ultrospec TM 3100 pro with SWIFT II software for 30 min at 308C. The negative control contained water instead of substrate. the manuscript. All authors read and approved the final manuscript.
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